ResultsIQ

ResultsIQ › Latest results › RPG Life Sciences Limited

RPG Life Sciences Limited strategy deck summary

NSE: RPGLIFE · BSE: 532983

Strategy deck of 2 Sep 2026, summarised by AI from the filing.

API business transferred to RPGAP via slump sale; external API sales were ₹95.1 cr in FY26.

Key takeaways

  1. API subsidiarization API business transferred to RPGAP via slump sale; external API sales were ₹95.1 cr in FY26.
  2. Raghava capacity Raghava facility has 300 KL installed capacity and 29 API molecules, 22 commercialized.

Original filing on BSE

RPG Life Sciences Limited Q1 FY27 results

As filed: Revenue ₹196 cr (+16% year on year), EBITDA ₹43.6 cr (+25% year on year), PAT ₹30.6 cr (+18% year on year), EBITDA margin 22.3% (+156 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹177 cr (+24% year on year), EBITDA ₹32.9 cr (+31% year on year), PAT ₹29.9 cr (−74% year on year), EBITDA margin 18.6% (+110 bps). Score 60 of 100, In line with trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin rose 110 bps year on year. Other income 31% of PBT. Share price after the results: +9.6% in 30 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹180 cr (+4% year on year), EBITDA ₹39.8 cr (−19% year on year), PAT ₹22.1 cr (−20% year on year), EBITDA margin 22.1% (−624 bps). Score 15 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were well below the company's own trend. EBITDA margin fell 624 bps year on year. Share price after the results: −8.0% in 30 days (Nifty 500: +2.8%).
  • Q2 FY26: Revenue ₹182 cr (+6% year on year), EBITDA ₹38.0 cr (−16% year on year), PAT ₹37.0 cr (−10% year on year), EBITDA margin 20.9% (−528 bps). Score 15 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were well below the company's own trend. EBITDA margin fell 528 bps year on year. Revenue rose ₹10.0 cr on a year ago, against ₹18.0 cr the year before. Share price after the results: +0.7% in 28 days (Nifty 500: +1.0%).
  • Q1 FY26: Revenue ₹169 cr (+2% year on year), EBITDA ₹35.0 cr (−10% year on year), PAT ₹26.0 cr (−4% year on year), EBITDA margin 20.7% (−293 bps). Score 17 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 293 bps year on year. Profit fell 78% from last quarter. Revenue rose ₹4.0 cr on a year ago, against ₹17.0 cr the year before. Share price after the results: −5.4% in 28 days (Nifty 500: −0.1%).
  • Q4 FY25: Revenue ₹143 cr (+13% year on year), EBITDA ₹25.0 cr (+25% year on year), PAT ₹117 cr (+39% year on year), EBITDA margin 17.5% (+173 bps). Score 55 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit before exceptional items growth was well above it. EBITDA margin rose 173 bps year on year. Tax rate 13%. Revenue fell 17% from last quarter. Profit before exceptional items rose ₹7.0 cr on a year ago, more than the ₹4.0 cr it added the year before. Share price after the results: +2.1% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹173 cr (+12% year on year), EBITDA ₹49.0 cr (+29% year on year), PAT ₹35.0 cr (+35% year on year), EBITDA margin 28.3% (+365 bps). Score 63 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 365 bps year on year.
  • Q2 FY25: Revenue ₹172 cr (+12% year on year), EBITDA ₹45.0 cr (+22% year on year), PAT ₹4.0 cr (+20% year on year), EBITDA margin 26.2% (+214 bps). Score 59 of 100, In line with trend. EBITDA margin rose 214 bps year on year. Tax rate 73%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

RPG Life Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.